Literature DB >> 16135621

Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.

Peter S Jensen1, Joe Albert Garcia, Sherry Glied, Maura Crowe, Mike Foster, Michael Schlander, Stephen Hinshaw, Benedetto Vitiello, L Eugene Arnold, Glen Elliott, Lily Hechtman, Jeffrey H Newcorn, William E Pelham, James Swanson, Karen Wells.   

Abstract

OBJECTIVE: Attention deficit hyperactivity disorder (ADHD) is a costly public health problem. To the authors' knowledge, this is the first study on the cost-effectiveness of the major forms of ADHD treatments used in NIMH's Multimodal Treatment Study of Children With ADHD (MTA Study).
METHOD: Five hundred seventy-nine children with ADHD, combined type, ages 7 to 9.9, were assigned to 14 months of medication management, behavioral treatment, both combined, or community care. Services were tallied throughout the study, including medication, health care visits, behavioral treatments, and rental costs. Provider specialty, total time, and number of visits with providers were used to calculate costs, adjusted to FY 2000 dollars with the consumer price index.
RESULTS: Treatment costs varied fourfold, with medication management being the least expensive, followed by behavioral treatment, and then combined treatment. Lower costs of medication treatment were found in the community care group, reflecting the less intensive (and less effective) nature of community-delivered treatment. Medical management was more effective but more costly than community care and more cost-effective than combination treatment and behavioral treatment alone. Under some conditions, combination treatment (medical management and psychotherapy) were somewhat more cost-effective, as demonstrated by lower costs per additional child "normalized" among children with multiple comorbid disorders.
CONCLUSIONS: Medical management treatment, although not as effective as combined medical management and behavioral treatment, is likely to be more cost-effective in routine treatment for children with ADHD, particularly those without comorbid disorders. For some children with comorbid disorders, it may be cost-effective to provide combination treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135621     DOI: 10.1176/appi.ajp.162.9.1628

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  40 in total

1.  Deciding on stimulant use for childhood ADHD: maintaining focus on the key questions.

Authors:  John D McLennan
Journal:  Can Fam Physician       Date:  2006-08       Impact factor: 3.275

2.  Measuring time costs in interventions designed to reduce behavior problems among children and youth.

Authors:  E Michael Foster; Deborah Johnson-Shelton; Ted K Taylor
Journal:  Am J Community Psychol       Date:  2007-09

Review 3.  A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).

Authors:  Desiree W Murray; L Eugene Arnold; Jim Swanson; Karen Wells; Karen Burns; Peter Jensen; Lily Hechtman; Natalya Paykina; Lauren Legato; Tara Strauss
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

4.  Prevalence of attention-deficit/hyperactivity disorder among children with vision impairment.

Authors:  Dawn K DeCarlo; Ellen Bowman; Cara Monroe; Robert Kline; Gerald McGwin; Cynthia Owsley
Journal:  J AAPOS       Date:  2014-02       Impact factor: 1.220

5.  Development of an internet-based support and coaching model for adolescents and young adults with ADHD and autism spectrum disorders: a pilot study.

Authors:  Elisabet Wentz; A Nydén; B Krevers
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-06-27       Impact factor: 4.785

6.  The Estimated Annual Cost of ADHD to the U.S. Education System.

Authors:  Jessica A Robb; Margaret H Sibley; William E Pelham; E Michael Foster; Brooke S G Molina; Elizabeth M Gnagy; Aparajita B Kuriyan
Journal:  School Ment Health       Date:  2011-09-01

Review 7.  Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Authors:  Michael Schlander
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

8.  [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].

Authors:  M Schlander; G-E Trott; O Schwarz
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

Review 9.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 10.  Co-occurring mental health problems and peer functioning among youth with attention-deficit/hyperactivity disorder: a review and recommendations for future research.

Authors:  Stephen P Becker; Aaron M Luebbe; Joshua M Langberg
Journal:  Clin Child Fam Psychol Rev       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.